iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : À¯·¡ ¼¼Æ÷ À¯Çüº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
Induced Pluripotent Stem Cells Market Size, Share & Trends Analysis Report By Derived Cell Type (Hepatocytes, Fibroblasts), By Application (Drug Development), By End-use, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå : 1553530
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 08¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 120 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,609,000
Unprintable PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠺Ұ¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,950 £Ü 10,055,000
Printable PDF (5-User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,949,000
Printable PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :

Grand View Research, Inc.ÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 33¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇϸç, 2024-2030³â CAGRÀº 10.21%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

iPS ¼¼Æ÷(iPSC) ½ÃÀåÀº ºü¸£°Ô ¼ºÀåÇϰí ÀÖÀ¸¸ç, iPS ¼¼Æ÷´Â ¹éÇ÷º´, ô¼ö ¼Õ»ó, ½ÉÇ÷°ü Áúȯ, ´ç´¢º´°ú °°Àº Áúº´°ú ½Î¿ì±â À§ÇØ ½Åü¿¡ ÇʼöÀûÀÎ ¸ðµç ¼¼Æ÷¿Í Á¶Á÷À» »ý¼ºÇÒ ¼ö ÀÖ´Ù´Â Á¡ÀÌ ±× Ȱ¿ëÀÇ ÁÖ¿äÇÑ ÀÌÀ¯ÀÔ´Ï´Ù. Ȱ¿ëÀÇ ÁÖ¿ä ÀÌÀ¯ÀÔ´Ï´Ù.

½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ´Ù¸¥ ¿äÀÎÀ¸·Î´Â ¿¬±¸ºñ Áõ°¡, À¯ÀüüÇÐ ±¸»ó Áõ°¡, ¸ÂÃãÇü Ä¡·á¿¡¼­ À¯Àüü °øÇÐÀÇ ÀÀ¿ëÀÌ ±ÞÁõÇÏ´Â °ÍÀ» µé ¼ö ÀÖ½À´Ï´Ù. ±× °á°ú iPSCÀÇ Ã¤ÅÃÀÌ °¡¼ÓÈ­µÇ¾î ½ÃÀå ¸ÅÃâ ¼ºÀåÀ¸·Î À̾îÁ³½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 10¿ù Axxam S.p.A.(Axxam S.p.A.)¿Í FUJIFILM Cellular Dynamics, Inc.´Â ½Å¾à °³¹ß ÇÁ·Î¼¼½º¸¦ ÃËÁøÇϱâ À§ÇÑ Àü·«Àû ÆÄÆ®³Ê½ÊÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ÆÄÆ®³Ê½ÊÀº Ç¥Àû Æò°¡, °í󸮷® ½ºÅ©¸®´×(HTS) ¹× °íÇÔ·® ½ºÅ©¸®´×À» °¡´ÉÇÏ°Ô ÇÏ´Â ÃÖ÷´Ü ½Å¾à °³¹ß ±â¼úÀ» »ç¿ëÇÏ¿© ½Å¾à °³¹ß ¿¬±¸ÀÚ¿Í °úÇÐÀڵ鿡°Ô hiPSC ±â¹Ý ºÐ¼®¿¡ ´ëÇÑ ÅëÇÕ Ç÷§Æû¿¡ ´ëÇÑ ¾×¼¼½º¸¦ Á¦°øÇÕ´Ï´Ù.

ÃÖ±Ù ÇコÄÉ¾î °³¹ß ¹× ¿¬±¸ µ¿ÇâÀÌ Å©°Ô È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ Ãß¼¼´Â ¿¹Ãø ±â°£ Áß iPS ¼¼Æ÷(ÀΰøÁٱ⼼Æ÷)¿¡ ´ëÇÑ ¼ö¿ä¿¡ Å« ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Á¤¹ÐÀÇ·á ºÐ¾ß¿¡¼­ Àΰ£ iPSC ¼¼Æ÷ÁÖÀÇ Àû¿ë ¹üÀ§°¡ È®´ëµÇ°í Áٱ⼼Æ÷ Ä¡·á ÀÀ¿ë¿¡ ´ëÇÑ °ü½ÉÀÌ ³ô¾ÆÁü¿¡ µû¶ó iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) ½ÃÀå È®´ë¿¡ Áß¿äÇÑ ¿äÀÎÀÌ µÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¿¹¸¦ µé¾î ¾ç»çÀÇ °øµ¿ ¼º¸í¿¡ µû¸£¸é 2021³â 3¿ù »ç³ª¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö´Â ÈÄÁöÇʸ§ ¼¿·ê·¯´ÙÀ̳ª¹Í½ºÀÇ iPSC Ç÷§ÆûÀ» »ó¾÷ÀûÀ¸·Î ÀÌ¿ë °¡´ÉÇÑ ¼¼Æ÷Ä¡·áÁ¦ Á¦Á¶¿¡ »ç¿ëÇÒ ¼ö ÀÖ´Â Çã°¡¸¦ ÃëµæÇß½À´Ï´Ù. ¼¼Æ÷ Ä¡·á´Â ¼¼Æ÷, Á¶Á÷, Àå±â µî Àΰ£ÀÇ »ý¹°ÇÐÀ» °³¼±, ¼öÁ¤, ´ëüÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ ¿¬±¸ Ȱµ¿ÀÌ È°¹ßÇØÁø °Íµµ iPSC¸¦ ÀÌ¿ëÇÑ ¿¬±¸¿¡ ÈûÀ» ½Ç¾îÁÖ¾ú½À´Ï´Ù. ¶ÇÇÑ SARS CoV-2 °¨¿°À» °ü¸®Çϱâ À§ÇÑ »õ·Î¿î Ä¡·á¹ý°ú Ä¡·á¹ýÀ» ¹ß°ßÇϱâ À§ÇÑ °úÇÐÀÚµéÀÇ Áö¼ÓÀûÀÎ ³ë·ÂÀº ¿¬±¸ Åø·Î¼­ iPSCÀÇ Çʿ伺À» ´õ¿í ³ôÀ̰í ÀÖ½À´Ï´Ù. ¶ÇÇÑ iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷)´Â »ý¸®ÇÐÀûÀ¸·Î µ¿µîÇÑ À¯±âü ¹× Àå±â ¸ðµ¨À» ¸¸µé ¼ö ÀÖÀ¸¹Ç·Î Àΰ£ÀÇ ¹ÙÀÌ·¯½º °¨¿° º´Å»ý¸® ¿¬±¸¿¡ Ȱ¿ëµÉ ¼ö ÀÖ½À´Ï´Ù. µû¶ó¼­ ÀÌ »ê¾÷ÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù.

¶ÇÇÑ iPS ¼¼Æ÷¿Í °ü·ÃµÈ ´Ù¾çÇÑ °úÇÐÀû Ȱµ¿¿¡ ÃÊÁ¡À» ¸ÂÃá »ê¾÷ÀÇ ¼ºÀå°ú ÇÔ²² Á¤ºÎ ¹× »ó¾÷ ºÎ¹®ÀÇ ÀÚ±Ý Áö¿øÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ´Ù¾çÇÑ ±â°üÀ» ÅëÇØ »ç¶÷µéÀÇ Áٱ⼼Æ÷¿¡ ´ëÇÑ Àνĵµ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº ¼¼Æ÷ ÃʱâÈ­ ºñ¿ë, À±¸®Àû ¹®Á¦, ½Ã°£ÀÌ ¿À·¡ °É¸®´Â °úÁ¤ µîÀÇ ¹®Á¦´Â iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) »ê¾÷ÀÇ ¼ºÀåÀ» ¾î´À Á¤µµ ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ³·Àº È¿À²¼º, ÀáÀçÀû Á¾¾ç À§Çè, ºÒÃæºÐÇÑ ÇÁ·Î±×·¡¹Öµµ iPSC ½ÃÀåÀÇ ¼ºÀåÀ» Á¦ÇÑÇÏ´Â ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

iPS¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå °³¿ä

Á¦3Àå iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) ½ÃÀå : À¯·¡ ¼¼Æ÷ À¯Çüº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå iPS ¼¼Æ÷(À¯µµ¸¸´ÉÁٱ⼼Æ÷) ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå °æÀï ±¸µµ

KSA
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Induced Pluripotent Stem Cells Market Growth & Trends:

The global induced pluripotent stem cells market size is expected to reach USD 3.31 billion by 2030, registering to grow at a CAGR of 10.21% from 2024 to 2030 according to a new report by Grand View Research, Inc. The market for induced pluripotent stem cells (iPSC) is expanding quickly. The ability of induced pluripotent stem cells to generate any cell or tissue essential by the body to fight or combat illnesses such as leukemia, spinal cord injury, cardiovascular disease, and diabetes is the primary reason for their utilization.

Other factors driving market expansion include higher research funding, an increase in the number of genomics initiatives, and a surge in the application of genome engineering in personalized drugs. This has accelerated the adoption of iPSC, resulting in the market's profitable revenue growth. For instance, in October 2020, Axxam S.p.A. & FUJIFILM Cellular Dynamics, Inc. announced a strategic partnership to advance the drug discovery process. Through the use of the most cutting-edge drug discovery techniques to enable target evaluation, High-Throughput Screening (HTS), & High-Content Screening, the partnership will give drug development researchers along with scientists access to an integrative platform of hiPSC-based assays.

Investments in healthcare development and research have expanded significantly in recent years, and this trend is projected to have a significant impact on induced pluripotent stem cell demand over the forecast period. The expanding spectrum of human iPSC cell lines' applications in precision medicine and the growing emphasis on stem cell therapeutic applications are predicted to be important factors driving induced pluripotent stem cell market expansion. For instance, in March 2021, Sana Biotechnology, Inc. received authorization to use FUJIFILM Cellular Dynamics' iPSC platform for the creation of commercially available cell therapies, according to a joint statement from both companies. Cell therapies can improve, fix, or substitute human biology, including cells, tissues, and organs.

The rise in research activity during the COVID-19 pandemic also enhanced iPSC-based research. In addition, scientists' ongoing efforts to discover novel therapies and treatments to manage the SARS CoV-2 infection have increased the need for iPSCs as research tools. Furthermore, induced pluripotent stem cells can create organoids or organ models that are physiologically equivalent, thus they can be utilized to study the pathophysiology of viral infection in humans. Thus, propelling the industry growth.

Furthermore, the government and commercial sectors are expanding funding along with growing industry that focuses on various scientific activities linked to iPSCs, and people are becoming more aware of stem cells through various organizations. However, challenges such as the high cost of cell reprograming, ethical concerns, and lengthy processes are inhibiting the growth of the induced pluripotent stem cell industry to a certain extend Moreover, low efficiency, potential tumor risk, and insufficient programming are other concerns restricting the expansion of the iPSC market.

Induced Pluripotent Stem Cells Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Induced Pluripotent Stem Cells Market Variables, Trends & Scope

Chapter 4. Induced Pluripotent Stem Cells Market: Derived Cell Type Estimates & Trend Analysis

Chapter 5. Induced Pluripotent Stem Cells Market: Application Estimates & Trend Analysis

Chapter 6. Induced Pluripotent Stem Cells Market: End Use Estimates & Trend Analysis

Chapter 7. Induced Pluripotent Stem Cells Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â